Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncofetal Antigen-Targeted Therapies.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLAP/ALPP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLAP/ALPP ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PLAP Products |
| Gene Delivery | PLAP/ALPP Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PLAP Products |
| Benchmark Ab | Anti-PLAP/ALPP (Sequence of NBE-002) Recombinant positive control. |
View PLAP Products |
| Validator | PLAP/ALPP siRNA Set For knockdown verification. |
View PLAP Products |
| Related Target A | ALPPL2 Highly homologous germ-cell isozyme; critical counter-screening target to ensure therapeutic specificity. |
View ALPPL2 Products |
| Related Target B | ALPL Tissue-nonspecific alkaline phosphatase; essential counter-screening target to avoid bone/kidney toxicity. |
View ALPL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-family selectivity screening (avoiding ALPL/ALPI off-target binding) | Human ALPP, ALPPL2, ALPI, and ALPL ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Shedding-mediated target sink evaluation | High-affinity recombinant proteins and shedding-resistant cell models generated via Lentiviral transduction. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PLAP/ALPP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLAP/ALPP therapeutics is intensifying, with major players shifting focus from traditional mAbs to next-generation Antibody-Drug Conjugates (ADCs) and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific epitopes to bypass cross-reactivity with closely related alkaline phosphatase family members.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Boehringer Ingelheim (NBE-002) | Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), NSCLC | Internalization Assay (Need high-purity ECD-Fc and native glycosylation) |
| CAR-T | Academic Institutions, Biotech Startups | Testicular Seminoma, Endometrial Cancer | Specificity Validation (Need cross-reactive and counter-screening panels for ALPPL2/ALPL) |
| Bispecific Ab | Novel Biotechs | Solid Tumors | Heterodimer Validation (Need high-purity monomeric antigens for SPR affinity profiling) |